相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors
Muna Qayed et al.
PEDIATRIC BLOOD & CANCER (2020)
The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a meta-analysis
Shuai Shao et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2020)
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
Pau Riera et al.
FRONTIERS IN PHARMACOLOGY (2020)
SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
Sarah Jannier et al.
Cancers (2020)
EXPLORING SIROLIMUS PHARMACOKINETIC VARIABILITY USING DATA AVAILABLE FROM THE ROUTINE CLINICAL CARE OF RENAL TRANSPLANT PATIENTS - POPULATION PHARMACOKINETIC APPROACH
Bojana Golubovic et al.
JOURNAL OF MEDICAL BIOCHEMISTRY (2019)
Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group
Tomoyuki Mizuno et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors
Kieuhoa T. Vo et al.
ONCOTARGET (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies
Tomoyuki Mizuno et al.
PEDIATRIC BLOOD & CANCER (2017)
Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
Aurelia Nguyen et al.
ONCOTARGET (2017)
The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model
Chie Emoto et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
mTOR inhibitors and diabetes
Bruno Verges et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Juan Martin-Liberal et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: AChildren's Oncology Group Phase I Consortium Report
Maryam Fouladi et al.
CLINICAL CANCER RESEARCH (2015)
Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2015)
P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
Seng Chuan Tang et al.
CLINICAL CANCER RESEARCH (2014)
Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Daniel A. Morgenstern et al.
PEDIATRIC BLOOD & CANCER (2014)
Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Children's Oncology Group Study
Rochelle Bagatell et al.
PEDIATRIC BLOOD & CANCER (2014)
Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation
Rakesh K. Goyal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
A. Naing et al.
BRITISH JOURNAL OF CANCER (2013)
Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1
Jeffrey R. Scott et al.
THERAPEUTIC DRUG MONITORING (2013)
Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside
Bruno Vincenzi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Efficacy and Comparative Effectiveness of Sirolimus as an Anticancer Drug
Melissa Hu et al.
LARYNGOSCOPE (2011)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
Erwan Pencreach et al.
CLINICAL CANCER RESEARCH (2009)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy
Asher D. Schachter et al.
PEDIATRIC TRANSPLANTATION (2006)
A Bayesian approach for population pharmacokinetic modelling of sirolimus
Chantaratsamon Dansirikul et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients
Y Böttiger et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Sirolimus - The evidence for clinical pharmacokinetic monitoring
SB Stenton et al.
CLINICAL PHARMACOKINETICS (2005)
Power, selection bias and predictive performance of the population pharmacokinetic covariate model
J Ribbing et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
WH Mondesire et al.
CLINICAL CANCER RESEARCH (2004)
Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats
K Arimori et al.
PHARMACEUTICAL RESEARCH (2003)
Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element
W El-Sankary et al.
DRUG METABOLISM AND DISPOSITION (2002)
Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients
L Bäckman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
X Wen et al.
DRUG METABOLISM AND DISPOSITION (2002)
Clinical pharmacokinetics of sirolimus
K Mahalati et al.
CLINICAL PHARMACOKINETICS (2001)
分享论文
